High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

Jean-Yves Blay,Nicolas Penel,Isabelle Ray-Coquard,Sophie Cousin,François Bertucci,Emmanuelle Bompas,Jean-Christophe Eymard,Esma Saada-Bouzid,Patrick Soulie,Pascaline Boudou-Rouquette,Armelle Dufresne,Axel Le Cesne,Olivier Mir,Laetitia Gambotti,Frederic Legrand,Clotilde Simon,Assia Lamrani Ghaouti,Sylvie Chevret,Christophe Massard

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

2021

Jean-Yves Blay
Nicolas Penel
Isabelle Ray-Coquard
Sophie Cousin
François Bertucci
Emmanuelle Bompas
Jean-Christophe Eymard
Esma Saada-Bouzid
Patrick Soulie
Pascaline Boudou-Rouquette
Armelle Dufresne
Axel Le Cesne
Olivier Mir
Laetitia Gambotti
Frederic Legrand
Clotilde Simon
Assia Lamrani Ghaouti
Sylvie Chevret
Christophe Massard

11520Background: AcSe Pembrolizumab is a Phase 2, non-randomized parallel arms, open-label, multicentric study from Unicancer investigating the efficacy and safety of pembrolizumab monotherapy in d...

Keywords:

Internal medicine
Medicine
Pembrolizumab
Chordoma
Sarcoma
Oncology
Alveolar soft part sarcoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations